BB&T Securities’s Tvardi Therapeutics TVRD Stock Holding History

BB&T Securities’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-499	Closed	-$429K	–	1621
2018 Q3	$429K	Buy	499 +182	+57%	+$131K	﹤0.01%	1158
2018 Q2	$218K	Buy	+317	New	+$161K	﹤0.01%	1419

Other funds holding TVRD

RCP

Rho Capital Partners New York $20.4M AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.17B AUM 42.44% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $5.91B AUM 53.97% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BB&T Securities's TVRD Position: Q4 2018 in Review

BB&T Securities sold out of Tvardi Therapeutics (TVRD) in Q4 2018, closing a stake of 499 shares — an estimated $429K sold.

BB&T Securities first reported a position in TVRD in Q2 2018 and held it in 2 quarters. The position peaked at $429K in Q3 2018. 134 funds tracked by Wall St. Rank hold TVRD as of Q4 2018.

BB&T Securities reported no remaining Tvardi Therapeutics position as of Q4 2018 after selling out during the quarter.
BB&T Securities sold 499 Tvardi Therapeutics shares in Q4 2018, an estimated $429K.
BB&T Securities first reported a position in Tvardi Therapeutics in Q2 2018 and held it in 2 quarters.
BB&T Securities's Tvardi Therapeutics position peaked at $429K in Q3 2018.
134 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2018.

Based on BB&T Securities's 13F filing for Q4 2018, filed 4 Feb 2019.